Doxil/Velcade Prolongs TTP in Myeloma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 2
Volume 16
Issue 2

The combination of liposomal doxorubicin (Doxil) and bortezomib (Velcade) significantly improved time to progression (TTP) in patients with relapsed or refractory multiple myeloma, compared with bortezomib alone

• ORLANDO—The combination of liposomal doxorubicin (Doxil) and bortezomib (Velcade) significantly improved time to progression (TTP) in patients with relapsed or refractory multiple myeloma, compared with bortezomib alone, according to a planned interim analysis of the phase III open-label, multicenter trial(DOXIL-MMY-3001). Robert Z. Orlowski, MD, PhD, of the University of North Carolina at Chapel Hill, presented the results at the 48th Annual Meeting of the American Society of Hematology (abstract 404).

The 646 patients had failed at least one prior therapy; they were randomized to bortezomib alone at 1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle or bortezomib at the same dose plus liposomal doxorubicin 30 mg/m2 on day 4.

For the combination, median TTP was 9.3 months vs 6.5 months for monotherapy (HR 1.82, P = .000004)). The overall response rate (48% vs 43%)

trended in favor of the combination. Response duration was significantly better with the combination (10.2 months vs 7.0 months, P = .0006). There was a trend toward improved overall survival with the combination (HR 1.48, P = .113). The incidence of serious adverse events was higher in the combination arm (36% vs 31%) but was judged to be acceptable. Ortho Biotech has filed a supplemental NDA for Doxil/Velcade for the treatment of myeloma.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content